Navigation Links
HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
Date:5/3/2011

BRANFORD, Conn., May 3, 2011 /PRNewswire/ -- HistoRx, Inc., announced today the launch of two new services for academic researchers interested in using AQUA® technology.  HistoRx's proprietary technology enables in situ analysis of biomarkers, including measurement of protein concentration with sub-cellular resolution in both whole tissue sections and tissue microarrays.  These highly quantitative, standardized and reproducible results take the guesswork out of IHC.

HistoRx provides AQUA analysis services for academic researchers interested in precise, accurate and reproducible protein expression quantification for their whole tissue or tissue microarray projects, giving researchers access to AQUA analysis without the cost of instrument purchase.  Academic scientists who want to use AQUA technology today have to buy a fluorescent digital microscopy system to acquire the images to be analyzed.  HistoRx recognizes that researchers often need high-quality data prior to the availability of funds for equipment purchase, such as proof-of-concept or grant support studies, and HistoRx wants to enable the expansion of AQUA technology's use into new areas.

"We've received several requests from universities to conduct one-time studies, or a short series of investigations, on their behalf for grant support," said Mark Gustavson, Assistant Director of Operations at HistoRx.  "AQUA analysis is a powerful tool and we want to ensure the widest possible access.  Providing the rigorous data to support development of new biological insights and clarify the benefits of a lab's eventual equipment purchase is in everyone's best interests."

In the Access AQUA® services program HistoRx will stain an investigator's slides, acquire digital fluorescent images, perform AQUA analysis, and provide the researcher with the images and the AQUA scores for the biomarkers of their choice.  This program is ideal for those conducting one or two experiments, or to demonstrate proof of concept for a grant application.

AQUAPrep™ services are tailored for those with several experiments in mind: the academic laboratory purchases a copy of AQUA software from HistoRx, HistoRx stains the slides, acquires digital fluorescent images, and sends the data files to the researcher for their own analysis using AQUA software.  This program enables researchers and their staff to become familiar with the use of the AQUAnalysis™ program prior to making an instrument investment.

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with any other method, digital or otherwise.  AQUA analysis is used in cancer research by over twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting occurred in 2010 with the launch by Genoptix Inc. (a subsidiary of Novartis) of diagnostic tests based on AQUA technology licensed from HistoRx. AQUA technology is currently available on the ScanScope FL™ from Aperio and will be available later this year on the Nuance™ and Vectra™ systems from Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
3. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
4. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
5. HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):